The 2021 American Society of Clinical Oncology Annual Meeting (ASCO2021) will be held in the form of a virtual meeting from June 4th to 8th.
Jiahe Bio-Bio released the latest research results of the Phase Ib trial of gelolimumab (GB226, geptanolimab) combined with fruquintinib in the treatment of patients with metastatic colorectal cancer (mCRC) at the ASCO conference.
According to the clinical trial data analysis of 15 patients with metastatic colorectal cancer (mCRC) selected as of December 15, 2020, the validity results are encouraging:
All evaluable enrolled patients:
The objective response rate (ORR) was 26.
7% in the phase II clinical recommended dose (RP2D) group, the objective response rate (ORR) was 33.
3%, the disease control rate (DCR) was 80%, and the median progression-free survival time (mPFS) was 7.
33 Month (95%CI: 1.
In 12 patients with MSS-type metastatic colorectal cancer (mCRC):
The objective response rate (ORR) was 25.
0%, the disease control rate (DCR) was 75%, and the median progression-free survival (mPFS) was 5.
45 months (95%CI: 1.
Security is controllable:
The most common treatment-related AEs (TRAE) were proteinuria (46.
7%), hypertension (46.
7%), and elevated AST (40.
7% of patients observed AEs above grade 3, and the most common was hypertension (20.
0 %); Level 4 and 5 TRAE are not observed
Gerolizumab is an IgG4K monoclonal antibody expressed in CHO cells, with a completely new amino acid sequence and molecular structure that is different from the anti-PD-1 monoclonal antibody already on the market.
The new drug marketing application of gerolizumab was officially accepted by the National Medical Products Administration (NMPA) on July 20, 2020, and was included in priority review for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL).
), the first anti-PD-1 monoclonal antibody to apply for PTCL indication in the world.